EcoDrugPlus

Proteasome Subunit Beta 11

Ensembl ID : ENSPNYG00000019144
Gene Symbol: PSMB11
1 Cross references
169 Possible Orthologues:

Proteasome Subunit Beta Type-11-Like

Ensembl ID : ENSPNYG00000012337
Gene Symbol: LOC102212057
3 Cross references
159 Possible Orthologues:

Proteasome Subunit Beta Type-5-Like

Ensembl ID : ENSPNYG00000019288
Gene Symbol: LOC102196183
3 Cross references
203 Possible Orthologues:

Proteasome Subunit Beta Type-6-Like

Ensembl ID : ENSPNYG00000015466
Gene Symbol: LOC102197382
3 Cross references
230 Possible Orthologues:

Proteasome Subunit Beta Type-7-Like

Ensembl ID : ENSPNYG00000007065
Gene Symbol: LOC102205309
3 Cross references
171 Possible Orthologues:

Proteasome Subunit Beta Type-9

Ensembl ID : ENSPNYG00000011803
Gene Symbol: LOC102200259
3 Cross references
208 Possible Orthologues:

Protein Arginine Methyltransferase 5

Ensembl ID : ENSPNYG00000019059
Gene Symbol: PRMT5
3 Cross references
198 Possible Orthologues:

Protein Farnesyltransferase Subunit Beta-Like

Ensembl ID : ENSPNYG00000000530
Gene Symbol: LOC102202474
3 Cross references
209 Possible Orthologues:

Protein Kinase C Alpha

Ensembl ID : ENSPNYG00000018254
Gene Symbol: PRKCA
3 Cross references
213 Possible Orthologues:

Protein Kinase C Beta

Ensembl ID : ENSPNYG00000018921
Gene Symbol: PRKCB
4 Cross references
207 Possible Orthologues:

Protein Kinase C Beta Type-Like

Ensembl ID : ENSPNYG00000014447
Gene Symbol: LOC102192349
3 Cross references
223 Possible Orthologues:

Protein Kinase C Delta

Ensembl ID : ENSPNYG00000005574
Gene Symbol: PRKCD
3 Cross references
204 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).